Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 5:263:115944.
doi: 10.1016/j.ejmech.2023.115944. Epub 2023 Nov 10.

Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids

Affiliations
Free article

Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids

Mathias Christophe Eymery et al. Eur J Med Chem. .
Free article

Abstract

Autotaxin (ATX) is an enzyme primarily known for the production of lysophosphatidic acid. Being involved in the development of major human diseases, such as cancer and neurodegenerative diseases, the enzyme has been featured in multiple studies as a pharmacological target. We previously found that the cannabinoid tetrahydrocannabinol (THC) could bind and act as an excellent inhibitor of ATX. This study aims to use the cannabinoid scaffold as a starting point to find cannabinoid-unrelated ATX inhibitors, following a funnel down approach in which large chemical libraries sharing chemical similarities with THC were screened to identify lead scaffold types for optimization. This approach allowed us to identify compounds bearing chromone and indole scaffolds as promising ATX inhibitors. Further optimization led to MEY-003, which is characterized by the direct linkage of an N-pentyl indole to the 5,7-dihydroxychromone moiety. This molecule has potent inhibitory activity towards ATX-β and ATX-ɣ as evidenced by enzymatic studies and its mode of action was rationalized by structural biology studies using macromolecular X-ray crystallography.

Keywords: Autotaxin; Cannabinoid; Chromones; Indoles; Inhibitors; Macromolecular X-ray crystallography; Molecular modelling; Structural biology.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors confirm that this article content has no conflict of interest. Findings regarding the potential applications of MEY-003 and analogs are the subject of E.U. patent application EP22215403.1, filed on December 21, 2022, owned by European Molecular Biology Laboratory, and Université Grenoble Alpes, and lists M.C.E., A.B., and A.A.M as inventors.

LinkOut - more resources